Those who listened to the ODAC committee morning session would no doubt recall the negativity of the FDA rep. I realise he was just doing his job, and in the long run, the fact that the FDA played a hard game could be a considerable advantage imo.
Amongst the FDA concerns were criticisms of the 'critical quality attributes' MSB proposed to use to measure the consistency, potency and effectiveness of batches of remestemcel-l.
From the briefing notes, the “FDA’s position is that the product attributes the Applicant has identified as related to potency and activity of the product, however, do not have a demonstrated relationship to the clinical performance of drug product lots, ....” And on it went.
My science qualifications are a little rusty, but it’s my understanding that Mesoblast believe the quality and potency of its MSC cell product lots can be gauged through monitoring the frequency of a number of cell surface markers, and particularly by the cells ability to inhibit production of the inflamatory cytokines, TNF-alpha and IL-2R alpha. The FDA weren’t convinced.
I suspect backroom discussions between the FDA and Mesoblast have been ongoing since August 13th. If the mechanism for monitoring quality and potency of MSC’s really is a stumbling block, it needs to be resolved.
Now by coincidence, a large study of Covid-19 patients in the Mount Sinai health system was published yesterday.
The study followed the clinical information, laboratory test results and patient outcomes, of 1484 individuals hospitalised with Covid-19 earlier this year. Long story short, the researchers concluded that high serum levels of IL-6 (P<0.0001) and TNF-alpha (P=0.0140) remained independent and significant predictors of disease severity and death, regardless of demographics and comorbidities.
Thinking out aloud again, given that remestemcel-l is proposed for use against both aGVHD and Covid-19, MSB already has TNF-alpha covered. I wonder what the FDA think about IL-6?
Nonetheless, my view is that, at least in paediatric conditions, if a treatment is safe and it works, that's enough. The Advisory Committee clearly agreed. 9-1.
Disclosure. I’m biased.
https://www.nature.com/articles/s41591-020-1051-9#Tab1
Herro
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
Those who listened to the ODAC committee morning session would...
-
- There are more pages in this discussion • 11,839 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 43856 | $1.11 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.11 | 66000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 52505 | 1.100 |
1 | 4552 | 1.095 |
3 | 60574 | 1.090 |
3 | 31716 | 1.085 |
2 | 14000 | 1.080 |
Price($) | Vol. | No. |
---|---|---|
1.110 | 66000 | 1 |
1.115 | 80808 | 1 |
1.120 | 88882 | 4 |
1.125 | 74996 | 5 |
1.130 | 111884 | 6 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |